HLS Therapeutics (TSE:HLS)‘s stock had its “outperform” rating reissued by research analysts at Raymond James in a research report issued to clients and investors on Tuesday, Stock Target Advisor reports. They currently have a C$28.00 target price on the stock. Raymond James’ price objective would suggest a potential upside of 49.02% from the company’s previous close.
Separately, Canaccord Genuity raised their target price on HLS Therapeutics to C$33.00 and gave the stock a “strong-buy” rating in a report on Friday, March 19th.
HLS traded down C$0.21 during midday trading on Tuesday, reaching C$18.79. 32,300 shares of the company were exchanged, compared to its average volume of 35,346. The company has a debt-to-equity ratio of 66.02, a quick ratio of 0.93 and a current ratio of 1.29. HLS Therapeutics has a one year low of C$13.35 and a one year high of C$21.76. The stock has a market capitalization of C$597.94 million and a P/E ratio of -31.58. The stock’s 50-day simple moving average is C$19.74 and its 200 day simple moving average is C$17.72.
About HLS Therapeutics
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. Its lead product is Clozaril, an atypical antipsychotic used in the treatment of schizophrenia.
Read More: Trade War
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.